NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers raised its position in NeoGenomics, Inc. (NASDAQ:NEO) by 2.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 389,003 shares of the medical research company’s stock after acquiring an additional 9,098 shares during the quarter. Rhumbline Advisers’ holdings in NeoGenomics were worth $6,411,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Nordea Investment Management AB increased its position in NeoGenomics by 2.8% in the 4th quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company’s stock valued at $1,301,000 after acquiring an additional 2,125 shares during the period. Geode Capital Management LLC grew its stake in shares of NeoGenomics by 1.2% in the third quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock worth $45,022,000 after purchasing an additional 36,136 shares in the last quarter. Jennison Associates LLC grew its stake in shares of NeoGenomics by 4.7% in the third quarter. Jennison Associates LLC now owns 1,276,468 shares of the medical research company’s stock worth $18,828,000 after purchasing an additional 57,041 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 987 shares during the period. Finally, Algert Global LLC raised its stake in shares of NeoGenomics by 204.3% during the third quarter. Algert Global LLC now owns 79,983 shares of the medical research company’s stock valued at $1,180,000 after purchasing an additional 53,700 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $10.40 on Thursday. NeoGenomics, Inc. has a 52-week low of $10.34 and a 52-week high of $19.11. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -16.77 and a beta of 1.23. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The stock’s fifty day simple moving average is $14.75 and its 200 day simple moving average is $15.33.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. As a group, sell-side analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on NEO. The Goldman Sachs Group decreased their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price objective for the company. Needham & Company LLC dropped their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Bank of America dropped their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.60.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.